PHVS
What one share of Pharvaris holds
Pharmaceutical Preparations
In our Phase 1 clinical trials to-date, we have observed rapid exposure and predictable linear pharmacokinetics (PK) with and without food. In addition, we observed deucrictibant to be a potent antagonist of the bradykinin B2 receptor, in vitro and in vivo with healthy volunteers.
Pharvaris’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$3.36 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.62 |
| Cash and investments | $5.25 |
| Book value | $4.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$1.05 | $0.00 | −$0.95 | — | $1.17 |
| 2019 | — | −$1.85 | $0.00 | −$1.54 | — | $4.32 |
| 2020 | — | −$6.11 | $0.01 | −$5.07 | — | $24.15 |
| 2021 | — | −$1.66 | $0.01 | −$1.74 | — | $7.00 |
| 2022 | — | −$2.39 | $0.00 | −$2.11 | — | $4.72 |
| 2023 | — | −$2.84 | $0.00 | −$2.62 | — | $8.12 |
| 2024 | — | −$2.69 | $0.01 | −$2.42 | — | $5.10 |
| 2025 | — | −$3.36 | $0.00 | −$2.62 | — | $4.88 |